Riociguat

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Riociguat
   1. Pharmacist Assessment Report
   2. Riociguat: Known uses and market status in Canada
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Canada Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Riociguat: Known uses and market status in Canada

Summary

The TxGNN deep-learning model has no candidate indication with a score of 0.99 or higher for Riociguat, so there is currently no new predicted indication. The drug’s recorded uses are listed below. They come from licenses and other recorded sources, not from model predictions.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	3
Evidence level	Not applicable
Canada Market Status	Marketed (marketed DINs: 10 of 10)
Number of DINs	10 (marketed: 10)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
pulmonary hypertension	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
chronic thromboembolic pulmonary hypertension
pulmonary arterial hypertension

Canada Market Information

Licence	Product	Dosage form	Status
02533588	SANDOZ RIOCIGUAT		Valid
02533561	SANDOZ RIOCIGUAT		Valid
02412764	ADEMPAS		Valid
02533618	SANDOZ RIOCIGUAT		Valid
02533596	SANDOZ RIOCIGUAT		Valid
02412802	ADEMPAS		Valid
02412799	ADEMPAS		Valid
02533545	SANDOZ RIOCIGUAT		Valid
02412772	ADEMPAS		Valid
02412810	ADEMPAS		Valid

Safety Considerations

• Drug Interactions: 75 interactions were identified. The 20 listed in the compiled data are all rated Moderate:
  • Proton pump inhibitors: omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole
  • Antacids and mineral products: aluminium hydroxide, calcium carbonate, magaldrate, magnesium carbonate, magnesium hydroxide, magnesium oxide
  • SGLT2 inhibitors: canagliflozin, dapagliflozin, empagliflozin, ertugliflozin
  • Others: clarithromycin, dexamethasone, mannitol, papaverine

Please refer to the package insert for warnings and contraindications.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---